Analyst Reco. AlloVir, Inc.

Equities

ALVR

US0198181036

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
0.798 ^USD	-1.05%		+0.11%	+17.39%

03-20	North American Morning Briefing : Markets on Hold -2-	DJ
03-15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	12-27	DJ
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	12-22	MT
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	12-22	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	12-22	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	12-22	MT
AlloVir Shares Rise After BofA Securities Cites 'Compelling Story,' Initiates Coverage With a Buy	18/08/23	MT
BofA Securities Starts AlloVir at Buy	18/08/23	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $16, Maintains Outperform Rating	26/04/23	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $25, Maintains Outperform Rating	23/01/23	MT
SVB Securities Adjusts Price Target on AlloVir to $25 From $24, Maintains Outperform Rating	07/11/22	MT
Morgan Stanley Cuts Price Target on AlloVir to $27 From $32, Maintains Overweight Rating	09/09/22	MT
Piper Sandler Adjusts AlloVir's Price Target to $30 From $34, Reiterates Overweight Rating	05/08/22	MT
SVB Securities Adjusts AlloVir's Price Target to $23 from $30, Keeps Outperform Rating	28/07/22	MT
Piper Sandler Adjusts AlloVir's Price Target to $34 From $55, Reiterates Overweight Rating	19/05/22	MT
SVB Leerink Adjusts AlloVir Price Target to $30 From $32, Maintains Outperform Rating	10/02/22	MT
BMO Capital Starts AlloVir at Outperform with $130 Price Target	01/02/22	MT
Morgan Stanley Adjusts AlloVir Price Target to $32 From $45, Maintains Overweight Rating	01/02/22	MT
Morgan Stanley Adjusts AlloVir's Price Target to $45 from $48, Keeps Overweight Rating	18/01/22	MT
SVB Leerink Adjusts AlloVir's Price Target to $32 from $37, Keeps Outperform Rating	17/12/21	MT
SVB Leerink Adjusts Price Target on AlloVir to $37 from $41, Keeps Outperform Rating	08/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AlloVir, Inc.

Equities

ALVR

US0198181036

Analyst Reco.

Filters